BAY ACC002

BAY ACC002 is a small molecule inhibitor of acetyl-CoA carboxylase 1 (ACC1) developed by Bayer. It targets the lipidation of ligands in the Wnt and Hedgehog (Hh) signaling pathways, which are critical for tumor-stroma communication in pancreatic cancer. By inhibiting ACC1, BAY ACC002 prevents the post-translational modification (lipidation) required for the secretion and activity of Wnt and Hh proteins. In preclinical studies, including patient-derived xenograft (PDX) models of pancreatic cancer, BAY ACC002 demonstrated anti-tumor efficacy and the ability to reduce the expression of β-catenin target genes, offering a potential therapeutic advantage over traditional Smoothened (Smo) inhibitors.